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Objective: The TNM staging system of lung cancer is widely used as a guide 
for estimating prognosis and selecting treatment lnodality. In 1997, the 
International Union Against Cancer and the American Joint Committee on 
Cancer have adopted a revised stage grouping for lung cancer. However, the 
validity of the new stage grouping has not been fully established. We 
investigated the prognoses of patients who had resection of non-small-cell 
lung cancer to confirm the validity of the revised classification. Methods: A 
total of 1310 patients with non-small-cell lung cancer underwent complete 
resection and pathologic staging of the disease in our hospitals from 1980 
through 1993. A pulmonary resection was performed with a systematic 
nodal dissection. The survivals were calculated with the Kaplan-Meier 
method on the basis of overall deaths, and the survival curves were 
compared by log rank test. Results: There were significant differences in 
survival between patients with T1 NO M0 and T2 NO M0 disease and 
between those with T1 N1 M0 and T2 N1 M0 disease. However, there was 
no significant difference between patients with T2 NO M0 disease and those 
with T1 NI M0 disease. No significant difference in survival was observed 
among patients with T2 N1 M0, T3 NO M0, and T3 N1 M0 cancer. Patients 
with different invaded organs of I"3 subdivision (pleura, chest wall, 
pericardium, or diaphragm) had a different prognosis. There was no 
significant difference between patients with T3 N2 M0 disease and those 
with stage I I IB disease. Conclusions: We supported most of the revision, 
such as dividing stage I, dividing stage II, and putting T3 NO M0 to stage 
lIB. Furthermore, we found some candidates for a subsequent revision, 
such as putting T3 N1 M0 to stage HB, putting T2 NO M0 and T1 N1 M0 
together, regarding diaphragm invasion as T4, and putting T3 N2 M0 to 
stage IIIB. (J Thorac Cardiovasc Surg 1998;116:407-11) 
T he TNM staging system of lung cancer is widely used as a guide for estimating prognosis and 
selecting treatment modal ity] -3 Recently some 
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questions have arisen about whether the present 
TNM staging really reflects the exact prognosis. 4 In 
1997, the International Union Against Cancer 
(UICC) and the American Joint Committee on 
Cancer have adopted a revised stage grouping. 5 
However, the validity of the new stage grouping has 
not been fully established. In this report, we inves- 
tigate the prognoses of 1310 patients with com- 
pletely resected non-small-cell lung cancer on the 
basis of the pathologic TNM classification to con- 
firm the validity of the revised classification and to 
analyze other prognostic factors. 
Patients and methods 
A total of 1310 patients with non-small-cell lung cancer 
underwent complete resection and pathologic staging of 
the disease in our hospitals from 1980 through 1993. In 
this period, chest computed tomography, brain computed 
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Table I. lhe characteristics of the 1310 patients in 
this study 
Characteristic No. of patients Pementage 
Sex* 
Male 968 73.9 
Female 342 26.1 
Histologic type 
SQ 556 42.4 
AD 645 49.3 
LA 109 8.3 
T factor 
T1 602 45.9 
T2 564 43.1 
T3 122 9.3 
T4 22 1.7 
N factor 
NO 803 61.3 
N1 245 18.7 
N2 260 19.8 
N3 2 0.2 
Stage 
Stage I 752 57.5 
Stage iI 197 15.0 
Stage I l lA 337 25.7 
Stage IllB 24 1.8 
SQ, Squamous cell carcinoma; AD, adenocarcinoma; LA, large cell carci- 
nolxla. 
"Age: 28 to 85 years (mean, 64.5 years). 
tomography, abdominal ultrasonography, and bonc scin- 
tigraphy were routinely performed before operation to 
evaluate distant metastasis. 4 A randomized trial for post- 
operative adjuvant chemotherapy was conducted in this 
period, but the results revealed no survival advantage or 
disadvantage with our regimen (unpublished data). Induc- 
tion therapy was not performed in this period especially 
for the patients who had been expecting a complete 
resection. A lobcctomy or a pneumonectomy was per- 
formed with the dissection of hilar and mediastinal lymph 
nodes (systematic nodal dissection('). Lymph nodes were 
numbered according to lymph node mapping reportcd by 
Naruke and associates. 7 The patients were classified on 
the basis of the pathologic TNM classification of the 
UICC. 5 Histologic typing was determined according to the 
World Health Organization classification, s The survivals 
were calculated with the Kaplan-Meier method on the 
basis of overall death including operative deaths, and the 
survival curves were compared by log rank test. 
Results 
Patients' characteristics and TNM distribution are 
shown in Tables I and II. Five-year survivals of 
patients with T1 NO M0, T2 NO M0, T1 N1 M0, and 
T2 N1 M0 diseases were 80%, 65%, 57%, and 42%, 
respectively (Fig. 1). There were significant differ- 
ences in survival between patients with T1 NO M0 
and T2 NO M0 diseases (P = .001) and between 
patients with T!  N1 M0 and T2 N1 M0 diseases 
Table II. The distribution of patients in the TNM 
subsets 
Stage (old) TNM subset No. of patients (%) 
Stage I T1 NO M0 480 (36.6) 
T2 NO M0 271 (20.6) 
Stage II T1 N1 M0 57 (4.4) 
T2 N1 M0 141 (10.8) 
Stage IlIA T3 NO M0 46 (3.5) 
T3 N1 M0 39 (3.0) 
T1 N2 M0 65 (5.0) 
T2 N2 M0 150 (11.4) 
T3 N2 M0 37 (2.8) 
Stage IIIB T4 NO M0 6 (0.5) 
T4 N1 M0 8 (0.6) 
T4 N2 M0 8 (0.6) 
T2 N3 M0 2 (0.2) 
(P = .02). However, there was no significant differ- 
ence between patients with T2 NO M0 and T1 NI 
M0 diseases. 
Fig. 2 shows survival curves of T2 Nl M0, T3 NO 
M0, and T3 N1 M0 diseases; there was no significant 
difference in survival among patients with T2 N1 M0 
(5-year survival, 42%), T3 NO M0 (5-year survival, 
34%), and T3 N1 M0 (5-year survival, 38%) dis- 
eases. 
To estimate the contribution of invaded organ to 
the prognosis, we compared survival curves of pa- 
tients with T3 N0-1 M0 disease according to the 
invaded organ (Fig. 3). Patients with T3 NO M0 
disease and patients with T3 N1 M0 disease were 
united for the estimation because they had similar 
survival curves, whereas patients with T3 N2 M0 
disease had significantly poorer prognoses. Patients 
with different invaded organs of T3 subdivision had 
different prognoses; pleura (5-year survival, 35%), 
chest wall (5-year survival, 26%), pericardium (5- 
year survival, 43%), and diaphragm (3-year survival, 
none) .  
Fig. 4 shows the survival curves of patients with 
T3 N2 M0 disease and patients with stage IIIB 
disease. The prognosis of patients with completely 
resected T3 N2 M0 disease (5-year survival, 11%) 
was poorer than that of patients with completely 
resected stage IIIB disease (5-year survival, 36%). 
There was no significant difference in survival be- 
tween patients with T3 N2 M0 disease and those 
with stage IlIB disease. 
Discussion 
The TNM staging system of lung cancer was 
revised in 1997. 5, ~'' 9 The staging system should be 
revised according to the prognosis of the patients 
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Fig. 1. The postoperative survival curves of patients with T1 NO M0, T2 NO M0, T1 N1 M0, and T2 N1 M0 
diseases how that there are significant diffcrences between the prognoses of patients with T1 NO M0 and 
T2 NO M0 diseases (P = .001) and between those of patients with T1 N1 M0 and T2 N1 M0 diseases (P 
.02). 
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Fig. 2. The postoperative survival curves show that there are no significant differences in the survivals 
among of patients with T2 N1 M0, T3 NO M0, and T3 N1 M0 diseases. 
who have relatively homogeneous backgrounds. In 
this present study, with which we attempted to assess 
the validity of the revision, we limited the cases to 
1980 through 1993 because preoperative xamina- 
tions in our institute were similar in this period. 4
In the revised TNM staging, stage I is divided into 
stage IA and stage lB. Stage II is also divided into 
stage I IA and stage IIB. Our results supported these 
divisions, because there were statistically significant 
differences between the prognoses of patients with 
T1 NO M0 and T2 NO M0 diseases and between 
those of patients with T1 N1 M0 and T2 N1 M0 
diseases. However, there was no difference between 
patients with T2 NO M0 and T1 N1 M0 diseases. 
Mountain 9 also reported that the suPdvals of pa- 
tients with T2 NO M0 and T1 N1 M0 diseases were 
57% and 55%. T2 NO M0 subgroup and T1 N1 M0 
subgroup may be included in the same group (it 
does not mean T1 N1 M0 should be included in 
stage I). 
T3 NO M0 subgroup is included in stage liB in 
the revised TNM staging. Because there was no 
difference between the prognosis of patients with 
T2 N1 M0 and T3 NO M0 diseases, our results 
supported the revision. On the other hand, T3 N1 
M0 is still controversial. Some investigators re- 
ported that patients with T3 N1 M0 diseases and 
patients with T3 N2 M0 diseases had a similar 
prognosis, l° However, others including US 2' 11, 12 
reported that patients with T3 N1 M0 diseases had 
a more preferable prognosis than patients with T3 
N2 M0 diseases. Mediastinal nodal involvement is
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Fig. 3. The postoperative survival curves of patients with T3 N0-1 M0 diseases how that, according to the 
invaded organ, patients with resected T3 tumors invading the diaphragm have a poor prognosis. 
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Fig. 4. The postoperative survival cm'ves of patients with T3 N2 M0 and stage IIIB diseases how that 
there is no significant difference between the prognoses. 
one of the most important prognostic factors and 
strongly influences urvival in patients with lung 
cancer. Although T3 N1 M0 may be another 
candidate of subgroup in stage IIB, further studies 
are required to find correct grouping. 
Some investigators 11 pointed out that T3 factors 
were heterogeneous. For the comparison of the 
prognosis according to the invaded organ, patients 
with N2 diseases were excluded to eliminate the 
influence of N factor. 13 In our patients with lung 
cancer invading diaphragm, there were no 3-year 
survivors. There has been only one report concern- 
ing the prognosis after the resection of the tumors 
invading the diaphragm} l' 14 Weksler and associ- 
ates/4 reported 8 cases with resected T3 tumors 
invading the diaphragm in which there were no 
4-year survivors, although 3 of the patients died of 
other causes. Some cancer cells in the lymph on the 
diaphragm flow to the abdominal ymph system, 
which is impossible to dissect. Tumors invading the 
diaphragm may be a candidate of T4 subgroup; 
however, the examination of a large number of 
cases, such as a multicenter study, is required. 
Patients with T3 N2 M0 diseases who have under- 
gone complete resection had poor prognoses. ~5 
There was no difference between the survival of 
patients with T3 N2 M0 diseases and that of patients 
with stage IIIB disease. One of the reasons for the 
similarity is that most of our patients with stage IIIB 
disease were selected cases (ie, only 2 patients had 
N3 disease and 64% of patients in the T4 classifica- 
tion had N0-1 diseases). However, it still suggests 
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that T3 N2 M0 diseases are extensively advanced 
and that the T3 N2 M0 subgroup may be included in 
stage IIIB. 
Most of our results supported the revision of the 
staging system proposed by the UICC and the AJCC 
in 1997. However, on the basis of our results, we 
present here some candidates for a subsequent 
revision. We ask for the assessment of our proposal 
by other investigators. After thorough discussions 
based on various results from different institutions, 
the next revision of the TNM staging would reflect 
the prognosis more precisely. 3'6 
We thank Ms. Mitsuko Hasegawa and Ms. Kayoko 
Aihara for their assistance. 
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